Boehringer Ingelheim sets aside olmutinib program
RIDGEFIELD, Conn.—In the wake of reevaluating the clinical data on olmutinib, a third-generation EGFR- targeted therapy, Boehringer Ingelheim will be returning the drug candidate's development and global commercialization rights to Hanmi Pharmaceutical Co. Ltd. Boehringer Ingelheim will not be launching new clinical trials for olmutinib, but will work with Hanmi Pharmaceutical to transition the current clinical development program back to the latter company.
“We would like to thank Hanmi Pharmaceutical for their collaboration and commitment during our joint development of olmutinib. Partnering is a key pillar of our oncology strategy at all stages of research and development, in order to offer cancer treatments that fit the needs of patients, caregivers and healthcare professionals. Boehringer Ingelheim’s oncology pipeline is robust and transformative, with several compounds currently in clinical development, and we strive for best-in-class, breakthrough cancer medications,” Dr. Jörg Barth, corporate senior vice president, therapeutic area head oncology, Boehringer Ingelheim, said of the decision.